pipeline | autoimmune/inflammation | oncology
A Phase I healthy volunteer study for ALPN-101 has begun. ALPN-202 is targeted to file an IND later in 2019.
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEA… twitter.com/i/web/status/11286…
May 15, 2019 1:07 pm
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2019 Financial Results. During the quart… twitter.com/i/web/status/11264…
May 9, 2019 11:32 am
© 2019 Alpine Immune Sciences.
All Rights Reserved, Alpine Immune Sciences Inc.